Circular Genomics Announces Closure of $15 Million Series A Financing to Advance First-in-Class Circular RNA Platform for Early Detection of Alzheimer's Disease

Circular Genomics宣布完成1500万美元A轮融资，用于推进其首创的环状RNA平台，以实现阿尔茨海默病的早期检测。

Financing accelerates clinical validation and commercial readiness, as circular RNAs emerge as a new category of brain-derived blood biomarkers with best-in-class performance

融资加速了临床验证和商业准备，因为环状RNA作为一类新的大脑衍生血液生物标志物，表现出同类最佳的性能。

SAN DIEGO, December 1, 2025-- Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and psychiatry, today announced the successful closure of a $15 million Series A financing round. The financing was led by Mountain Group Partners, with participation from Poplar Grove Investors, HIP Fund, and the Alzheimer's Drug Discovery Foundation (ADDF).

圣地亚哥，2025年12月1日——Circular Genomics, Inc. 是神经学和精神病学领域基于环状RNA的精准医疗工具的世界领先开发商，今天宣布成功完成了1500万美元的A轮融资。本轮融资由Mountain Group Partners领投，Poplar Grove Investors、HIP Fund和阿尔茨海默病药物发现基金会（ADDF）参与投资。

This transformative capital will accelerate the clinical development and commercialization of Circular Genomics' proprietary circRNA biomarker platform for the early detection of Alzheimer's disease (AD), advancing the company's mission to reshape the standard of care for all neurological disorders..

这笔转型资本将加速Circular Genomics专有的circRNA生物标志物平台的临床开发和商业化，用于阿尔茨海默病（AD）的早期检测，推动公司重塑所有神经系统疾病治疗标准的使命。

'This Series A financing represents a pivotal milestone in our journey to transform precision neurology, including Alzheimer's disease diagnosis and patient care,' said Paul Sargeant, Chief Executive Officer of Circular Genomics. 'The strong support from our world-class investors validates the breakthrough potential of our circular RNA platform and underscores the urgent need for accessible, comprehensive blood-based biomarkers that can detect Alzheimer's biology at the earliest stages.

“这次A轮融资代表了我们在转变精准神经学，包括阿尔茨海默病诊断和患者护理的旅程中一个关键的里程碑，”Circular Genomics首席执行官保罗·萨金特表示。“我们世界级投资者的强力支持验证了我们的环状RNA平台的突破潜力，并突显了对能够在最早阶段检测阿尔茨海默病生物学的可及、全面的血液生物标志物的迫切需求。”

With this capital, we are positioned to advance our clinical programs, expand our world-class team, and bring our first transformative test in Alzheimer's disease to patients and physicians who desperately need better diagnostic tools.'.

有了这笔资金，我们有能力推进我们的临床项目，扩充我们世界级的团队，并将我们首个变革性的阿尔茨海默病检测工具带给迫切需要更好诊断工具的患者和医生。

The Series A proceeds will be deployed strategically to advance multiple high-priority initiatives:

A轮融资将被战略性地用于推动多个高优先级的项目：

• Clinical Validation: Expanding clinical validation studies to demonstrate the platform's utility across diverse patient populations and healthcare settings

• 临床验证：扩大临床验证研究，以展示该平台在不同患者群体和医疗环境中的实用性

• Platform Innovation: Enhancing the circRNA biomarker platform to expand beyond Alzheimer's disease into other neurodegenerative and psychiatric disorders

• 平台创新：增强circRNA生物标志物平台，扩展到阿尔茨海默病以外的其他神经退行性疾病和精神疾病

• Strategic Partnerships: Establishing collaborations with leading academic institutions, pharmaceutical companies, and diagnostic service providers

• 战略合作伙伴关系：与领先的学术机构、制药公司和诊断服务提供商建立合作关系

• Team Expansion: Recruiting world-class talent across clinical development, regulatory affairs, commercial operations, and scientific research

• 团队扩张：在临床开发、监管事务、商业运营和科学研究领域招聘世界级人才

The Unmet Need for Early Alzheimer's Detection

早期阿尔茨海默病检测的未满足需求

Alzheimer's disease affects more than 7 million Americans, with diagnosis often delayed by 2-3 years after symptom onset. It is the most prevalent type of dementia, accounting for up to 80% of all dementia cases, making it the leading cause of cognitive decline among older adults. Despite this prominence, approximately 75% of all dementia cases go undiagnosed, and among patients with diagnosed dementia, roughly 50% receive no formal diagnosis.

阿尔茨海默病影响着超过700万美国人，其诊断通常在症状出现后延迟2至3年。它是痴呆症中最常见的类型，占所有痴呆病例的80%，是老年人认知能力下降的主要原因。尽管如此普遍，大约75%的痴呆病例仍未被诊断，而在已确诊的痴呆患者中，约50%未获得正式诊断。

Traditional diagnostic methods, including PET imaging and cerebrospinal fluid testing, are expensive, invasive, and not widely accessible. The recent approval of disease-modifying therapies has created an unprecedented urgency for accurate, accessible blood-based biomarkers that can identify patients at the earliest disease stages—when interventions may have the most profound impact on disease trajectory..

传统诊断方法，包括PET成像和脑脊液检测，昂贵、具有侵入性且不易普及。近期对疾病修饰治疗的批准，使得迫切需要准确且可及的血液生物标志物来识别疾病最早期的患者——此时干预可能对疾病进程产生最深远的影响。

A Transformative Solution: Circular RNA as a New Class of Blood Biomarkers

一种变革性的解决方案：环状RNA作为一类新型的血液生物标志物

Alzheimer's disease is now recognized as a biologically detectable condition long before clinical symptoms appear—yet current diagnostic solutions face significant limitations in accessibility, specificity, and pathway-level resolution. Despite recent advances, there remains a critical need for biomarkers that capture the full complexity of disrupted molecular pathways driving AD pathogenesis..

阿尔茨海默病现在被认为是一种在临床症状出现之前很久就可以通过生物学手段检测到的疾病——但目前的诊断方法在可及性、特异性和通路水平分辨率方面面临显著限制。尽管最近有所进展，但仍迫切需要能够捕捉驱动阿尔茨海默病发病机制的分子通路紊乱全貌的生物标志物。

Circular Genomics' circRNA platform directly addresses this gap. Circular RNAs—highly stable, brain-enriched non-coding RNAs—regulate many of the core biological and pathogenic pathways altered in AD, including neuroinflammation, oxidative stress, synaptic dysfunction, neural plasticity, and amyloid/tau pathology.

Circular Genomics的circRNA平台直接填补了这一空白。环状RNA——高度稳定、大脑中富集的非编码RNA——调控许多在阿尔茨海默病（AD）中发生改变的核心生物和致病途径，包括神经炎症、氧化应激、突触功能障碍、神经可塑性以及淀粉样蛋白/tau蛋白病理。

The company's generated data demonstrated:.

公司生成的数据表明：。

• Robust prediction models benchmarked against CSF, amyloid PET, and leading plasma biomarkers

• 针对脑脊液、淀粉样蛋白PET和领先的血浆生物标志物进行基准测试的稳健预测模型

• Identification of pre-symptomatic individuals at risk for progression to symptomatic AD

• 识别有进展为症状性AD风险的无症状个体

• Specificity for AD relative to other dementias, addressing a major barrier in early-stage diagnosis

• 相对于其他痴呆症，对阿尔茨海默病的特异性，解决了早期诊断中的一个主要障碍

This unique molecular signature reflects disease biology across the full AD continuum and provides a holistic, real-time window into brain health unprecedented among existing diagnostic modalities. 'The convergence of disease-modifying therapies and innovative blood-based diagnostics is creating a transformational moment in Alzheimer's disease care,' added Andrew Lechleiter, Chief Executive Officer at Poplar Grove Investors, LLC.

这种独特的分子特征反映了整个阿尔茨海默病连续体的疾病生物学，并提供了一个整体的、实时的大脑健康窗口，这在现有的诊断方式中是前所未有的。Poplar Grove Investors有限责任公司首席执行官安德鲁·莱希莱特补充道：“疾病修饰疗法和基于血液的创新诊断方法的结合，正在创造阿尔茨海默病护理的变革时刻。”

'Circular Genomics' circRNA platform stands out for its ability to capture the complex biology of Alzheimer's disease across multiple pathogenic pathways, which can provide clinicians with actionable insights, potentially even before memory and thinking issues emerge, that can fundamentally change patient care trajectories.

“Circular Genomics”的circRNA平台因其能够捕捉阿尔茨海默病在多条致病通路中的复杂生物学特性而脱颖而出，这可以为临床医生提供可操作的见解，甚至可能在记忆和思维问题出现之前，从而从根本上改变患者的治疗轨迹。

The team's progress in building a best-in-class biomarker signature, coupled with their strategic vision for market development, gives us tremendous confidence in their ability to execute and positively impact the lives of people affected by Alzheimer's disease.'.

该团队在构建一流的生物标志物特征方面取得的进展，加上他们在市场开发方面的战略眼光，使我们对他们执行任务的能力以及对阿尔茨海默病患者生活的积极影响充满极大的信心。

Robust Data Generating a Potentially New Standard of Care

稳健的数据生成可能成为新的护理标准

Building on the company's recent presentation at the Clinical Trials on Alzheimer's Disease (CTAD) Conference, where findings demonstrated the platform's potential to shift AD diagnosis from a reactive, late-stage process to an early, proactive, biologically grounded assessment, Circular Genomics is now positioned to deliver a new class of precision neurology diagnostics..

基于公司最近在阿尔茨海默病临床试验（CTAD）会议上展示的成果，这些发现表明该平台有潜力将阿尔茨海默病的诊断从被动、晚期的过程转变为早期、主动且基于生物学的评估，Circular Genomics目前正准备推出一类全新的精准神经学诊断工具。

The company's whole-blood transcriptomic models capture a broad landscape of disease-relevant circRNA signatures, enabling:

该公司的全血转录组模型捕捉到了与疾病相关的广泛circRNA特征，能够实现：

• Earlier detection before cognitive decline becomes clinically apparent

• 在认知能力下降变得临床明显之前及早发现

• More precise patient stratification for disease-modifying therapies

• 针对疾病修饰疗法的更精确患者分层

• Improved longitudinal monitoring of disease progression and therapeutic response

• 改进了对疾病进展和治疗反应的纵向监测

• Integration into primary care, expanding access to early intervention

• 融入初级保健，扩大早期干预的可及性

These capabilities have the potential to fundamentally transform AD patient management—from identification of early disease biology and risk assessment to treatment selection and disease monitoring. By providing an accurate, accessible, and comprehensive molecular assessment of Alzheimer's disease, Circular Genomics empowers physicians to identify patients at the earliest stages of the disease—even before symptoms appear—and match them with appropriate preventative interventions or disease-modifying therapies..

这些能力有潜力从根本上改变阿尔茨海默病患者的管理方式——从早期疾病生物学的识别和风险评估，到治疗选择和疾病监测。通过提供准确、可及且全面的阿尔茨海默病分子评估，Circular Genomics 赋予医生在疾病最早阶段（甚至在症状出现之前）识别患者的能力，并为他们匹配适当的预防性干预措施或疾病修饰疗法。

'Circular Genomics represents a rare opportunity to invest in a truly transformative diagnostic platform that addresses one of healthcare's most pressing unmet needs,' said Joe Cook III, Managing Director at Mountain Group Partners. 'The company's circular RNA technology provides a fundamentally different and more comprehensive view of Alzheimer's disease biology than existing biomarkers.

“循环基因组学代表了一个难得的机会，可以投资于一个真正具有变革性的诊断平台，解决医疗保健领域最紧迫的未满足需求之一，”Mountain Group Partners董事总经理乔·库克三世表示。“该公司的环状RNA技术比现有生物标志物提供了更根本、更全面的阿尔茨海默病生物学视角。

Combined with the team's world-class scientific expertise and the compelling clinical data they have generated; we believe Circular Genomics is uniquely positioned to become the leader in precision neurology diagnostics. We are honored to support their mission to enable earlier detection and better treatment outcomes for millions of patients.'.

结合团队世界级的科学专业知识和他们生成的引人注目的临床数据，我们相信Circular Genomics在精准神经学诊断领域具有独特的领导地位。我们很荣幸支持他们的使命，使数百万患者能够更早地检测和获得更好的治疗效果。

About Circular Genomics

关于循环基因组学

Circular Genomics is the world-leading developer of circular RNA-based precision medicine tools, data and diagnostics for precision neurology and psychiatry. Leveraging exclusive licenses and pioneering technologies in circular RNA, Circular Genomics is aiming to reshape the standard of care for the early identification of neurological and psychiatric diseases such as Alzheimer's disease, Parkinson's disease, major depressive disorder, and bipolar disorder.

Circular Genomics 是全球领先的基于环状RNA的精准神经学和精神病学药物、数据和诊断工具的开发者。凭借在环状RNA领域的独家许可和开创性技术，Circular Genomics 致力于重塑神经系统和精神疾病（如阿尔茨海默病、帕金森病、重度抑郁症和双相情感障碍）早期识别的护理标准。

Initial products include assays to assess and tailor optimal patient management care pathways resulting in more personalized and effective delivery of care. The company's proprietary circRNA biomarker platform integrates advanced transcriptomics to generate sophisticated models of disease risk and progression, providing comprehensive insights into the multiple disrupted pathways critical to disease biology and pathology.

初始产品包括用于评估和定制最佳患者管理护理路径的检测方法，从而实现更个性化和有效的护理。该公司专有的circRNA生物标志物平台整合了先进的转录组学技术，生成复杂的疾病风险和进展模型，为疾病生物学和病理学中多个关键的紊乱通路提供全面的见解。

For additional details, please visit www.circulargenomics.com..

有关更多详细信息，请访问 www.circulargenomics.com。